Zonghan Dai

Title: Zonghan Dai: Innovator in Protein Interaction Technologies

Introduction

Zonghan Dai is a prominent inventor based in Englewood, CO (US). He has made significant contributions to the field of protein interaction technologies, holding a total of 2 patents. His work focuses on proteins that interact with specific protein tyrosine kinases, which are crucial for various therapeutic and diagnostic applications.

Latest Patents

Zonghan Dai's latest patents include the development of the Abl-interactor protein. This invention relates to a protein that interacts with the cAb1 protein tyrosine kinase and includes a nucleic acid sequence encoding the same. The invention also encompasses complexes of the protein and cAb1, which can be utilized in identifying therapeutic and diagnostic agents. Another significant patent is the ABL-interactor protein, which similarly involves a protein that interacts with the cAbl protein tyrosine kinase, along with its corresponding nucleic acid sequence. This invention also focuses on the complexes formed with cAbl and their potential applications in therapeutic and diagnostic agent identification.

Career Highlights

Zonghan Dai is affiliated with Duke University, where he continues to advance his research in protein interactions. His innovative work has positioned him as a key figure in the scientific community, contributing to the understanding of protein functions and their implications in health and disease.

Collaborations

Zonghan has collaborated with notable colleagues, including Ann-Marie Pendergast and Ann Marie Pendergast, enhancing the impact of his research through shared expertise and insights.

Conclusion

Zonghan Dai's contributions to the field of protein interaction technologies are noteworthy, with his patents paving the way for advancements in therapeutic and diagnostic applications. His work exemplifies the importance of innovation in addressing complex biological challenges.